Ying-Chun Shen
Overview
Explore the profile of Ying-Chun Shen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lee L, Chiang C, Shen Y, Wu S, Shih Y, Yang T, et al.
ACS Nano
. 2022 Dec;
17(1):84-93.
PMID: 36575141
In this work, a low-power memristor based on vertically stacked two-dimensional (2D) layered materials, achieved by plasma-assisted vapor reaction, as the switching material, with which the copper and gold metals...
12.
Shao Y, Feng Y, Yen C, Yang T, Shen Y, Chao Y, et al.
J Formos Med Assoc
. 2022 Sep;
121(12):2430-2437.
PMID: 36153210
Background: The combination of bevacizumab and atezolizumab has been established as a standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). We examined the treatment outcomes of patients in Taiwan...
13.
Chen B, Liang P, Shih T, Liu T, Shen Y, Lu L, et al.
Eur Radiol
. 2022 Jul;
33(1):512-522.
PMID: 35864351
Objectives: To investigate the association of sarcopenia, myosteatosis, and sarcopenic obesity with survival outcomes among patients who underwent immunotherapy for advanced hepatocellular carcinoma (HCC). Methods: In this retrospective analysis, patients...
14.
Liu T, Shen Y, Cheng A
J Formos Med Assoc
. 2022 Apr;
121(8):1371-1383.
PMID: 35400583
Rapidly expanding armamentarium of systemic therapy for advanced hepatocellular carcinoma (HCC) occurred in the recent few years. Multikinase inhibitors (MKI) or targeted therapy with antiangiogenic properties have been the focus...
15.
Zucali P, Lin C, Carthon B, Bauer T, Tucci M, Italiano A, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35058326
Background: Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion and thus...
16.
Shen Y, Wang C, Liou K, Tan P, Wang Y, Wu S, et al.
Small
. 2021 Nov;
18(5):e2104168.
PMID: 34821034
A multifunctional ion-sensitive floating gate Fin field-effect transistor (ISFGFinFET) for hydrogen and sodium detection is demonstrated. The ISFGFinFET comprises a FGFET and a sensing film, both of which are used...
17.
Shih Y, Shen Y, Cheng Y, Chaudhary M, Yang T, Yu Y, et al.
ACS Appl Mater Interfaces
. 2021 Nov;
13(46):55470-55480.
PMID: 34775743
A conductive-bridge random access memory (CBRAM) has been considered a promising candidate for the next-generation nonvolatile memory technology because of its excellent performance, for which the resistive switching behavior depends...
18.
Shen Y, Yeh C, Jeng Y, Hsu C, Hsu C, Lin Z, et al.
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680292
Purpose: Tumor-infiltrating tissue-resident memory CD8 T cells (CD8 T; CD103+ CD8+) are considered tumor-specific and may correlate better with the tumor response to immune checkpoint blockade (ICB). This study evaluated...
19.
Shen Y, Lee P, Kuo Y, Wu W, Chen C, Lei C, et al.
J Hepatocell Carcinoma
. 2021 Aug;
8:809-822.
PMID: 34336726
Background: Gut microbiome has been associated with the efficacy of immune checkpoint inhibitors (ICI) in patients with various types of cancers but not yet in hepatocellular carcinoma (HCC). Aims: To...
20.
Wu T, Shen Y, Cheng A
Kaohsiung J Med Sci
. 2021 Jul;
37(8):643-653.
PMID: 34213069
Advanced hepatocellular carcinoma (HCC) was considered an inherently refractory tumor in the chemotherapy era (1950-2000). However, systemic therapy has evolved to molecular targeted therapy and immunotherapy, and nine treatment regimens...